CV Sciences (CVSI) EBIT (QoQ) (2011 - 2026)
CV Sciences (CVSI) EBIT (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | CV Sciences | 4.11 Mn | 3.80 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -324.00% |
| Dec 31, 2025 | 72.73% |
| Sep 30, 2025 | -109.92% |
| Jun 30, 2025 | -1,290.91% |
| Mar 31, 2025 | 101.70% |
| Dec 31, 2024 | -89.44% |
| Sep 30, 2024 | 41.51% |
| Jun 30, 2024 | 5.97% |
| Mar 31, 2024 | 30.26% |
| Dec 31, 2023 | -103.43% |
| Sep 30, 2023 | 59.39% |
| Jun 30, 2023 | -118.67% |
| Mar 31, 2023 | 371.15% |
| Dec 31, 2022 | -138.23% |
| Sep 30, 2022 | 61.47% |
| Jun 30, 2022 | -52.81% |
| Mar 31, 2022 | 82.87% |
| Dec 31, 2021 | -196.74% |
| Sep 30, 2021 | 15.10% |
| Jun 30, 2021 | -12.75% |